Anaptysbio (ANAB) Operating Leases (2021 - 2026)

Anaptysbio (ANAB) has 6 years of Operating Leases data on file, last reported at $11.5 million in Q1 2026.

• Quarterly Operating Leases fell 15.57% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 15.57% YoY) and the FY2025 annual result came in at $12.0 million, down 14.74% from the prior year.
• Operating Leases fell to $11.5 million in Q1 2026, from $12.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $20.2 million in Q2 2022 to a low of $11.5 million in Q1 2026.
• A 5-year average of $15.8 million and a median of $16.0 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases dropped 2.67% — and 2025, when it declined 22.73%.
• Tracing ANAB's Operating Leases over 5 years: stood at $17.8 million in 2022, then retreated by 9.97% to $16.0 million in 2023, then retreated by 12.0% to $14.1 million in 2024, then decreased by 14.74% to $12.0 million in 2025, then declined by 4.48% to $11.5 million in 2026.
• The last three Operating Leases figures came in at $11.5 million (Q1 2026), $12.0 million (Q4 2025), and $12.6 million (Q3 2025), per Business Quant data.